The results of splenectomy for hematologic disorders in 200 patients have been evaluated. Anticipated good results were achieved in all patients with hereditary spherocytosis and over 80% of patients with idiopathic thrombocytopenic purpura. A hematologic improvement in patients with thrombotic thrombocytopenic purpura, thalassemia, myeloid metaplasia, and malignant hemopathy occurred in a significant percentage of cases. The overall in-hospital mortality was 7% but was totally related to the primary disease process. It was concluded that the results justify broadening the indications for splenectomy in patients with hematologic disorders.